{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:47:26Z","timestamp":1777877246700,"version":"3.51.4"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["801481"],"award-info":[{"award-number":["801481"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015459","name":"Danish Cancer Society Research Center","doi-asserted-by":"publisher","award":["R231-A13820"],"award-info":[{"award-number":["R231-A13820"]}],"id":[{"id":"10.13039\/100015459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015459","name":"Danish Cancer Society Research Center","doi-asserted-by":"publisher","award":["R368-A21555"],"award-info":[{"award-number":["R368-A21555"]}],"id":[{"id":"10.13039\/100015459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015459","name":"Danish Cancer Society Research Center","doi-asserted-by":"publisher","award":["R231-A13832"],"award-info":[{"award-number":["R231-A13832"]}],"id":[{"id":"10.13039\/100015459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF19OC0058603"],"award-info":[{"award-number":["NNF19OC0058603"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF22OC0080995"],"award-info":[{"award-number":["NNF22OC0080995"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015459","name":"Danish Cancer Society Research Center","doi-asserted-by":"publisher","award":["R336-A19402-22-S44"],"award-info":[{"award-number":["R336-A19402-22-S44"]}],"id":[{"id":"10.13039\/100015459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011076","name":"Simon Fougner Hartmanns Familiefond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","award":["ZIA-BC-010816"],"award-info":[{"award-number":["ZIA-BC-010816"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Urokinase plasminogen activator receptor\u2013associated protein (uPARAP) is a collagen-internalizing receptor with emerging relevance as a therapeutic target. The involvement of uPARAP in extracellular matrix turnover and stromal remodeling within the tumor microenvironment (TME) makes it an especially promising target in tumors with a high stromal component. Mesothelioma, characterized by its unique complex TME, is a highly refractory cancer type for which no effective targeted therapy exists. uPARAP has been shown to be expressed across all subtypes of mesothelioma, especially in the sarcomatoid and biphasic subtypes, suggesting that a uPARAP-targeted therapy may benefit a specific patient population. In this study, we utilized an antibody\u2013drug conjugate (ADC) comprising an anti-uPARAP mAb conjugated to monomethyl auristatin E via a protease-sensitive linker for preclinical studies on mesothelioma treatment. Using mouse xenograft models with a human mesothelioma cell line or a patient-derived mesothelioma cell isolate, we demonstrated a strong anticancer effect following treatment with the uPARAP-targeting ADC. IHC studies revealed this to be the case, even in tumors exhibiting a heterogeneous expression of uPARAP, suggesting that uPARAP-expressing cancer-associated fibroblasts also play a role in the anticancer effect through a bystander mechanism. Furthermore, we show that combination treatment with cisplatin, commonly used in first-line mesothelioma therapy, leads to a strongly enhanced anticancer effect relative to treatment with either drug alone. Our study demonstrates the potential utility of a uPARAP-targeted ADC as a therapeutic option for mesothelioma, alone or in combination with chemotherapeutics. This perspective is particularly emphasized by a recently initiated clinical trial with a humanized anti-uPARAP ADC for the treatment of other malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study highlights the translational promise of a uPARAP-targeted ADC for the treatment of mesothelioma, a cancer lacking effective therapies. Demonstrating potent preclinical efficacy and synergy with cisplatin, our findings support the clinical advancement of a uPARAP-directed ADC strategy, particularly considering an ongoing clinical trial evaluating this approach in other malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0381","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T04:53:46Z","timestamp":1765342426000},"page":"130-142","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting uPARAP with an Antibody\u2013Drug Conjugate Exhibits Efficacy against Mesothelioma and Synergizes with Cisplatin"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8384-5209","authenticated-orcid":false,"given":"P\u0131nar","family":"\u00c7ak\u0131lkaya","sequence":"first","affiliation":[{"name":"1Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4226-975X","authenticated-orcid":false,"given":"Ida Marie","family":"Egeland Larsen","sequence":"additional","affiliation":[{"name":"1Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1611-2595","authenticated-orcid":false,"given":"Qun","family":"Jiang","sequence":"additional","affiliation":[{"name":"2Thoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1299-0991","authenticated-orcid":false,"given":"Kirstine","family":"Sandal N\u00f8rregaard","sequence":"additional","affiliation":[{"name":"1Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0691-3567","authenticated-orcid":false,"given":"Henrik","family":"G\u00e5rdsvoll","sequence":"additional","affiliation":[{"name":"1Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8590-5233","authenticated-orcid":false,"given":"Jingli","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Thoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-2307","authenticated-orcid":false,"given":"Henrik Jessen","family":"J\u00fcrgensen","sequence":"additional","affiliation":[{"name":"1Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6834-6743","authenticated-orcid":false,"given":"Michaela","family":"Hansen Blomquist","sequence":"additional","affiliation":[{"name":"1Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3783-8288","authenticated-orcid":false,"given":"Alba","family":"Martinez Perlado","sequence":"additional","affiliation":[{"name":"1Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4032-0426","authenticated-orcid":false,"given":"Oliver","family":"Krigslund","sequence":"additional","affiliation":[{"name":"1Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2283-3535","authenticated-orcid":false,"given":"Eric","family":"Santoni-Rugiu","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark."},{"name":"4Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-1232","authenticated-orcid":false,"given":"Lars Henning","family":"Engelholm","sequence":"additional","affiliation":[{"name":"1Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4012-3633","authenticated-orcid":false,"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[{"name":"2Thoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1833-3922","authenticated-orcid":false,"given":"Niels","family":"Behrendt","sequence":"additional","affiliation":[{"name":"1Finsen Laboratory, Rigshospitalet\/Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark."},{"name":"4Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026011610011154700_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026011610011154700_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"2026011610011154700_bib3","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3390\/cancers12051186","article-title":"Malignant pleural mesothelioma: genetic and microenviromental heterogeneity as an unexpected reading frame and therapeutic challenge","volume":"12","author":"Abbott","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026011610011154700_bib4","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"2026011610011154700_bib5","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1038\/srep06152","article-title":"Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma","volume":"4","author":"Hudson","year":"2014","journal-title":"Sci Rep"},{"key":"2026011610011154700_bib6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO-24-02425","article-title":"Treatment of pleural mesothelioma: ASCO guideline update","volume":"43","author":"Kindler","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026011610011154700_bib7","doi-asserted-by":"crossref","first-page":"1203073","DOI":"10.3389\/fimmu.2023.1203073","article-title":"Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy","volume":"14","author":"Aggarwal","year":"2023","journal-title":"Front Immunol"},{"key":"2026011610011154700_bib8","doi-asserted-by":"crossref","first-page":"11452","DOI":"10.3390\/ijms222111452","article-title":"The collagen receptor uPARAP in malignant mesothelioma: a potential diagnostic marker and therapeutic target","volume":"22","author":"\u00c7ak\u0131lkaya","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026011610011154700_bib9","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1038\/s41467-021-23583-1","article-title":"Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis","volume":"12","author":"Jungwirth","year":"2021","journal-title":"Nat Commun"},{"key":"2026011610011154700_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1369\/jhc.6A7133.2006","article-title":"Increased expression of the collagen internalization receptor uPARAP\/Endo180 in the stroma of head and neck cancer","volume":"55","author":"Sulek","year":"2007","journal-title":"J Histochem Cytochem"},{"key":"2026011610011154700_bib11","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ijc.10227","article-title":"Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells","volume":"98","author":"Schnack Nielsen","year":"2002","journal-title":"Int J Cancer"},{"key":"2026011610011154700_bib12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1083\/jcb.200411153","article-title":"Intracellular collagen degradation mediated by uPARAP\/Endo180 is a major pathway of extracellular matrix turnover during malignancy","volume":"169","author":"Curino","year":"2005","journal-title":"J Cell Biol"},{"key":"2026011610011154700_bib13","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3892\/ijo.2015.3120","article-title":"The collagen receptor uPARAP\/Endo180 in tissue degradation and cancer (Review)","volume":"47","author":"Melander","year":"2015","journal-title":"Int J Oncol"},{"key":"2026011610011154700_bib14","doi-asserted-by":"crossref","first-page":"e9808","DOI":"10.1371\/journal.pone.0009808","article-title":"A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion","volume":"5","author":"Huijbers","year":"2010","journal-title":"PLoS One"},{"key":"2026011610011154700_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/path.4661","article-title":"Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP\/Endo180","volume":"238","author":"Engelholm","year":"2016","journal-title":"J Pathol"},{"key":"2026011610011154700_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/1535-7163.MCT-22-0312","article-title":"Endo180 (MRC2) antibody\u2013drug conjugate for the treatment of sarcoma","volume":"22","author":"Evans","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026011610011154700_bib17","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1158\/0008-5472.CAN-06-3496","article-title":"The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo","volume":"67","author":"Wienke","year":"2007","journal-title":"Cancer Res"},{"key":"2026011610011154700_bib18","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/labinvest.3780354","article-title":"The urokinase plasminogen activator receptor-associated protein\/endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis","volume":"81","author":"Engelholm","year":"2001","journal-title":"Lab Invest"},{"key":"2026011610011154700_bib19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1242\/jcs.113.6.1021","article-title":"Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor","volume":"113","author":"Sheikh","year":"2000","journal-title":"J Cell Sci"},{"key":"2026011610011154700_bib20","doi-asserted-by":"crossref","first-page":"100003","DOI":"10.1016\/j.mbplus.2019.03.002","article-title":"CCL2\/MCP-1 signaling drives extracellular matrix turnover by diverse macrophage subsets","volume":"1","author":"J\u00fcrgensen","year":"2019","journal-title":"Matrix Biol Plus"},{"key":"2026011610011154700_bib21","doi-asserted-by":"crossref","first-page":"127640","DOI":"10.1016\/j.bmcl.2020.127640","article-title":"Evaluation of PNU-159682 antibody drug conjugates (ADCs)","volume":"30","author":"Holte","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"2026011610011154700_bib22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12885-015-1362-2","article-title":"Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma","volume":"15","author":"Kalra","year":"2015","journal-title":"BMC Cancer"},{"key":"2026011610011154700_bib23","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/1078-0432.CCR-16-1667","article-title":"Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient\u2013derived xenografts and mesothelin as a biomarker of tumor response","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026011610011154700_bib24","article-title":"The recycling collagen receptor uPARAP is a unique mediator of stromal drug delivery to carcinoma cells","author":"N\u00f8rregaard","year":"2025  16","journal-title":"Mol Cancer Ther"},{"key":"2026011610011154700_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-1759(98)00189-6","article-title":"Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology","volume":"222","author":"List","year":"1999","journal-title":"J Immunol Methods"},{"key":"2026011610011154700_bib26","doi-asserted-by":"crossref","first-page":"26996","DOI":"10.1074\/jbc.M110.208033","article-title":"The non-phagocytic route of collagen uptake","volume":"286","author":"Madsen","year":"2011","journal-title":"J Biol Chem"},{"key":"2026011610011154700_bib27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10020-021-00306-2","article-title":"The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells","volume":"27","author":"Po\u017aniak","year":"2021","journal-title":"Mol Med"},{"key":"2026011610011154700_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-62703-541-5_16","article-title":"Drug-to-antibody ratio (DAR) by UV\/Vis spectroscopy","volume":"1045","author":"Chen","year":"2013","journal-title":"Methods Mol Biol"},{"key":"2026011610011154700_bib29","doi-asserted-by":"crossref","first-page":"44605","DOI":"10.18632\/oncotarget.17883","article-title":"The collagen receptor uPARAP\/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers","volume":"8","author":"Nielsen","year":"2017","journal-title":"Oncotarget"},{"key":"2026011610011154700_bib30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"key":"2026011610011154700_bib31","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/cancers15153886","article-title":"Antibody-drug conjugates: a review of approved drugs and their clinical level of evidence","volume":"15","author":"Gogia","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026011610011154700_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.yexcr.2003.10.008","article-title":"uPARAP\/endo180 directs lysosomal delivery and degradation of collagen IV","volume":"293","author":"Kj\u00f8ller","year":"2004","journal-title":"Exp Cell Res"},{"key":"2026011610011154700_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1248\/cpb.c19-00853","article-title":"Antibody\u2013drug conjugate payloads; study of Auristatin derivatives","volume":"68","author":"Akaiwa","year":"2020","journal-title":"Chem Pharm Bull"},{"key":"2026011610011154700_bib34","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2026011610011154700_bib35","doi-asserted-by":"crossref","first-page":"1699768","DOI":"10.1080\/19420862.2019.1699768","article-title":"Clinical pharmacology of vc-MMAE antibody\u2013drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies","volume":"12","author":"Li","year":"2020","journal-title":"MAbs"},{"key":"2026011610011154700_bib36","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/1535-7163.MCT-16-0688","article-title":"Highly potent, anthracycline-based antibody-drug conjugates generated by enzymatic, site-specific conjugation","volume":"16","author":"Stefan","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2026011610011154700_bib37","first-page":"3199","article-title":"Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model","volume":"47","author":"Reale","year":"1987","journal-title":"Cancer Res"},{"key":"2026011610011154700_bib38","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","article-title":"LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates","volume":"78","author":"Purcell","year":"2018","journal-title":"Cancer Res"},{"key":"2026011610011154700_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"2026011610011154700_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"20244","journal-title":"J Hematol Oncol"},{"key":"2026011610011154700_bib41","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.trecan.2022.06.009","article-title":"Drug independence and the curability of cancer by combination chemotherapy","volume":"8","author":"Pomeroy","year":"2022","journal-title":"Trends Cancer"},{"key":"2026011610011154700_bib42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2026011610011154700_bib43","first-page":"349","article-title":"Chapter twenty-three - antibody\u2013drug conjugates for targeted cancer therapy","volume-title":"Annual reports in medicinal chemistry [Internet]","author":"Goldmacher","year":"2012"},{"key":"2026011610011154700_bib44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10157-024-02490-x","article-title":"An integrated view of cisplatin-induced nephrotoxicity, hepatotoxicity, and cardiotoxicity: characteristics, common molecular mechanisms, and current clinical management","volume":"28","author":"Oliveira","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"2026011610011154700_bib45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"2026011610011154700_bib46","doi-asserted-by":"crossref","first-page":"e28771","DOI":"10.1002\/pbc.28771","article-title":"LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies","volume":"68","author":"Slemmons","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2026011610011154700_bib47","doi-asserted-by":"crossref","first-page":"17631","DOI":"10.3390\/ijms242417631","article-title":"Generation and characterization of SORT1-targeted antibody\u2013drug conjugate for the treatment of SORT1-positive breast tumor","volume":"24","author":"Zhuang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026011610011154700_bib48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to Increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026011610011154700_bib49","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/antib11040078","article-title":"Delivery of drugs into cancer cells using antibody-drug conjugates based on receptor-mediated endocytosis and the enhanced permeability and retention effect","volume":"11","author":"Tashima","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"2026011610011154700_bib50","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1535-7163.MCT-16-0710","article-title":"Inhibition of megakaryocyte differentiation by antibody\u2013drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol Cancer Ther"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0381\/3712186\/crc-25-0381.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/1\/130\/3725838\/crc-25-0381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/1\/130\/3725838\/crc-25-0381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T15:01:28Z","timestamp":1768575688000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/1\/130\/771757\/Targeting-uPARAP-with-an-Antibody-Drug-Conjugate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0381","relation":{},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}